Supporting Information

Rec. Nat. Prod. 17:4 (2023) 731-736

A New Isobenzofuranone Derivative from Arctic Fungus *Gyoerffyella* sp. CPCC 401434

Bingyuan Zhang^{1,2,3}, Yan Tang^{1,2}, Zhe Guo¹, Jun Hu¹, Qingrong Du¹,

Tao Zhang¹, Shengjun Dai², Baiping Ma^{3*}, Liyan Yu^{1*} and Dewu Zhang^{1*}

¹ Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

> ² School of Pharmacy, Yantai University, Yantai 264005, China ³ Paliting Institute of Palitician Madising Palitics 100850, China

> ³ Beijing Institute of Radiation Medicine, Beijing 100850, China

Table of Contents	Page
Figure S1: HR-ESI-MS spectrum of 1	2
Figure S2: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 1	2
Figure S3: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 1	3
Figure S4: DEPT spectrum of 1	3
Figure S5: HSQC spectrum of 1	4
Figure S6: HMBC spectrum of 1	4
Figure S7: UV spectrum of 1	5
Figure S8: ECD spectrum of 1	5
Figure S9: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 2	6
Figure S10: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 2	6
Figure S11: HSQC spectrum of 2	7
Figure S12: HMBC spectrum of 2	7
Figure S13: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 3	8
Figure S14: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 3	8
Figure S15: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 4	9
Figure S16: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 4	9
Figure S17: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 5	10
Figure S18: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 5	10
Figure S19: HSQC spectrum of 5	11
Figure S20: HMBC spectrum of 5	11
Figure S21: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 6	12
Figure S22: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 6	12
Figure S23: ¹ H-NMR (600 MHz, CDCl ₃) spectrum of 7	13
Figure S24: ¹³ C-NMR (150 MHz, CDCl ₃) spectrum of 7	13
Figure S25: The Scifinder similarity report for new compound 1	14
Spectroscopic data of the compounds 2-7	15
Cytotoxic activity assays	15
Antibacterial activity assays	16



Figure S2: ¹H-NMR (600 MHz, CDCl₃) spectrum of 1



Figure S3: ¹³C-NMR (150 MHz, CDCl₃) spectrum of 1



Figure S4: DEPT spectrum of 1













Figure S7: UV spectrum of 1



Figure S8: ECD spectrum of 1



Figure S10: ¹³C-NMR (150 MHz, CDCl₃) spectrum of 2









© 2023 ACG Publications. All rights reserved.



Figure S14: ¹³C-NMR (600 MHz, DMSO-*d*₆) spectrum of **3**



Figure S16: ¹³C-NMR (150 MHz, CDCl₃) spectrum of 4



Figure S18: ¹³C-NMR (150 MHz, DMSO-*d*₆) spectrum of 5









Figure S22: ¹³C-NMR (150 MHz, DMSO-*d*₆) spectrum of 6



Figure S24: ¹³C-NMR (150 MHz, DMSO-*d*₆) spectrum of 7



← Return to Home

Substances search for drawn structure



Figure S25: The Scifinder similarity report for new compound 1

Spectroscopic Data of the Compounds 2-7

(*R*)-3-acetyl-7-hydroxy-5-methoxyl-3H-isobenzofuran-l-one (2): $[\alpha]^{25}_{D}$ +127.2 (*c* 0.08, MeOH); ESIMS *m*/*z* 251 [M+H]⁺; CD (MeOH) λ_{max} ($\Delta\epsilon$): 215 (-17.5), 241 (+4.8), 286 (+5.0) nm; ¹H and ¹³C NMR data, see Table 1.

Banksialactone D (**3**): ESIMS *m*/*z* 267 [M+H]⁺; ¹H NMR (600 MHz, DMSO-*d*₆) δ_{H} : 6.68 (1H, s, H-7), 5.14 (1H, d, *J* = 6.6 Hz, 4-OH), 4.08 (1H, m, H-3), 3.93 (3H, s, H-12), 3.90 (3H, s, H-13), 2.09 (3H, s, H-11), 1.61 (3H, s, H-10), 0.70 (3H, d, *J* = 6.6 Hz, H-9); ¹³C NMR (150 MHz, DMSO-*d*₆) δ_{C} : 166.9 (C-1), 164.0 (C-6), 157.6 (C-8), 152.7 (C-4a), 110.9 (C-5), 104.8 (C-8a), 95.6 (C-7), 88.1 (C-4), 68.7 (C-3), 56.4 (C-12), 55.7 (C-13), 21.0 (C-10), 17.1 (C-9), 11.1 (C-11).

(3R,4S)-3,8-dihydroxy-3-hydroxymethyl-6-methoxy-4,5-dimethyl-isochroman-1-one (4): ESIMS m/z 269 [M+H]⁺; ¹H NMR(600 MHz, CDCl₃) $\delta_{\rm H}$: 11.24 (1H, s, 8-OH), 6.38 (1H, s, H-7), 4.08 (1H, br s, Ha-9), 3.85 (3H, s, H-12), 3.69 (1H, m, Hb-9), 3.28 (1H, q, J = 6.6 Hz, H-4), 2.07 (3H, s, H-11), 1.17 (3H, d, J = 6.6 Hz, H-10); ¹³C NMR (150 MHz, CDCl₃) $\delta_{\rm H}$: 168.7 (C-1), 164.9 (C-6), 163.3 (C-8), 141.8 (C-4a), 115.6 (C-5), 99.4 (C-8a), 97.7 (C-7), 65.8 (C-9), 55.9 (C-12), 36.3 (C-4), 15.6 (C-10), 10.2 (C-11).

1-O-[α -*L*-*rhamnopyranosyl*]-2,5-*dimethyl*-3-*phenol* (5): [α]²⁵_D -123.3 (*c* 0.01, MeOH); ESIMS *m/z* 283 [M-H]⁻; ¹H NMR (600 MHz, DMSO-*d*₆) δ_{H} : 6.36 (1H, s, H-6), 6.30 (1H, s, H-4), 5.23 (1H, d, *J* = 1.8 Hz, H-1'), 3.81 (1H, m, H-2'), 3.65 (1H, m, H-3'), 3.46 (1H, m, H-5'), 3.26 (1H, m, H-4'), 2.15 (3H, s, H-8), 1.92 (3H, s, H-7), 1.10 (3H, d, *J* = 6.6 Hz, H-6'),; ¹³C NMR (150 MHz, DMSO-*d*₆) δ_{C} : 155.9 (C-3), 154.9 (C-1), 135.2 (C-5), 109.7 (C-2), 109.4 (C-4), 106.2 (C-6), 98.3 (C-1'), 71.9 (C-4'), 70.6 (C-3'), 70.4 (C-2'), 69.5 (C-5'), 21.2 (C-8), 18.0 (C-6'), 8.3 (C-7).

p-hydroxybenzaldehyde (6): ESIMS m/z 123 [M+H]⁺; ¹H NMR (600 MHz, DMSO- d_6) $\delta_{\rm H}$: 9.71 (1H, s, H-7), 7.69 (2H, d, J = 8.4 Hz, H-3, H-5), 6.84 (2H, d, J = 8.4 Hz, H-2, H-6); ¹³C NMR (150 MHz, DMSO- d_6) $\delta_{\rm C}$: 190.4 (C-7), 165.9 (C-4), 132.2 (C-2, C-6), 127.0 (C-1), 116.4 (C-3, C-5).

2-(4-hydroxyphenyl) ethanol (7): ESIMS m/z 139 [M+H]⁺; ¹H NMR(600 MHz, DMSO- d_6) $\delta_{\rm H}$: 9.17 (1H, s, 4'-OH), 6.98 (2H, d, J = 8.4 Hz, H-2', H-6'), 6.65 (2H, d, J = 8.4 Hz, H-3', H-5'), 4.57 (1H, br s, 1-OH), 3.51 (2H, t, J = 7.2 Hz, H-1), 2.59 (2H, t, J = 7.2 Hz, H-2); ¹³C NMR (150 MHz, DMSO- d_6) $\delta_{\rm C}$: 155.5 (C-4'), 129.7 (C-1'), 129.4 (C-2', C-6'), 114.9 (C-3', C-5'), 62.6 (C-1), 38.3 (C-2).

Cytotoxic Activity Assays

MTT assay was used to measure the cytotoxicities of compounds. Five human cancer cell lines (HeLa, HCT116, HepG2, A549, and H460) were obtained from ATCC. Cells (5×10^3 cells/well) were

added to 96-well culture dishes and grown for 24 h followed by the addition of fresh medium (100mL) and the test compound. After an additional 48 h, the media was removed and fresh media with MTT solution was added. The cells were incubated for 1 h and then the optical density at 450 nm was determined. Compounds 1–7 were tested for five cancer cell lines at three concentrations (50, 5, 0.5 μ M). Each concentration of the compounds was tested in three parallels. IC₅₀ values for each cell line were determined with Sigmaplot software.

Antibacterial Activity Assays

The minimal inhibitory concentrations (MICs) of the isolated compounds were determined by the broth microdilution method in 96-well plates according to Clinical and Laboratory Standards Institute. All the test strains used in this study were standard strains obtained from American Type Culture Collection (ATCC), and levofloxacin was used as positive control. The final concentrations of compounds ranged from 0.5 to 64 μ g/mL. Culture plates were incubated at 37 °C for 18 h. The MICs were defined as the lowest concentration that prevented visible growth of the bacteria.